Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPA.0000000000001061 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lenvatinib is a tyrosine kinase inhibitor that is being used to treat neuroendocrine tumors based on the success shown in the TALENT trial. There are two documented cases of lenvatinib-induced pancreatitis in patients being treated for thyroid cancer. This report describes the first case of pancreatitis seen in a patient with a metastatic neuroendocrine tumor being treated with lenvatinib.
View Article and Find Full Text PDFLenvatinib, a tyrosine kinase inhibitor (TKI), is a stronger inhibitor of vascular endothelial growth factor receptor, fibroblast growth factor receptors 1 to 4, and platelet-derived growth factor receptor (PDGFR) than other TKIs. We herein report a 77-year-old Japanese woman who received the minimum dose of lenvatinib for treatment of hepatocellular carcinoma. Within one month of starting treatment, she developed severe proteinuria, hypertension, and renal dysfunction.
View Article and Find Full Text PDFLenvatinib-Induced Acute Pancreatitis in a Patient with Metastatic Thyroid Cancer: A Case Report.
Int J Gen Med
September 2020
Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Republic of Korea.
Background: Lenvatinib, a novel multi-target tyrosine kinase inhibitor, has been approved for treating differentiated thyroid cancer. Herein, we describe a rare case of acute pancreatitis that developed during lenvatinib treatment in a 65-year-old man with recurrent thyroid cancer.
Case Presentation: The patient was admitted to our department following a complaint of acute-onset epigastric pain and indigestion.
Lenvatinib-induced acute acalculous cholecystitis in a patient with hepatocellular carcinoma.
Clin J Gastroenterol
August 2020
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
The patient was a 67-year-old man with advanced hepatocellular carcinoma (HCC) due to chronic hepatitis B. Due to refractoriness to radiofrequency ablation and transcatheter arterial chemoembolization, lenvatinib, a new oral mutikinase inhibitor, was started with a daily dose of 12 mg. However, on day 6 the patient developed acute-onset, right upper quadrant pain associated with fever; laboratory tests revealed leukocytosis and liver dysfunction.
View Article and Find Full Text PDFLenvatinib-Induced Acute Pancreatitis Associated With a Pancreatic Pseudocyst and Splenic Pseudoaneurysms.
Pancreas
July 2018
Department of Gastroenterology and Hepatology Faculty of Medicine Center for Digestive Disease and Division of Endoscopy University of Miyazaki Hospital Miyazaki, Japan Department of Medical Oncology University of Miyazaki Hospital Miyazaki, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!